Skip to content
Open access · OA via OpenAlex

Mesenchymal Stem Cells Therapy for Muscular Atrophy and Sarcopenia

Junzheng Yang

Epidemiology International Journal · 2022

Abstract

Sarcopenia is characterized by a loss of skeletal muscle mass, strength and function, and badly influence health and quality of the patients, the prevalence of sarcopenia is increasing particularly in the people aged 65 years or above, and the phenomena of chronic-inflammation and inflamm-aging is a major reason to multitude of geriatric conditions including sarcopenia.With the rapid development of regenerative medicine, Mesenchymal stem cells therapy showed a potential possibility to treat or alleviate the symptoms of muscular atrophy and sarcopenia.Here, we will summarize the recent progress of Mesenchymal stem cells therapy on muscular Atrophy and sarcopenia, which may provide some ideas for aging-related or degenerative diseases treatment.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.23880/eij-16000231
Canonical
link ↗
Fetched
2026-10-10 MST

Cite this

APA
Yang, J. (2022). Mesenchymal Stem Cells Therapy for Muscular Atrophy and Sarcopenia. <em>Epidemiology International Journal</em>. https://doi.org/10.23880/eij-16000231
Vancouver
Yang J. Mesenchymal Stem Cells Therapy for Muscular Atrophy and Sarcopenia. Epidemiology International Journal. 2022. doi:10.23880/eij-16000231.
BibTeX
@article{junzheng2022Mesenc, title = {Mesenchymal Stem Cells Therapy for Muscular Atrophy and Sarcopenia}, author = {Junzheng Yang}, journal = {Epidemiology International Journal}, year = {2022}, doi = {10.23880/eij-16000231}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings